BioCentury
ARTICLE | Financial News

Regeneron falls after reporting earnings

February 10, 2016 1:27 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shed $24.56 to $365.97 on Tuesday after reporting 4Q15 and 2015 financial results that missed expectations and guiding to slower growth of 2016 U.S. sales of ophthalmic drug Eylea aflibercept.

Regeneron's 4Q15 total revenues were $1.1 billion, up 37% from $802 million in 4Q14 but short of the $1.2 billion consensus estimate. Full-year revenues were $4.1 billion, up 46% from $2.8 billion in 2014 but shy of the $4.2 billion consensus. ...